Table 2 Clinical characteristics for patients with and without subsequent nephrotoxicity in the first cycle
From: Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study
Characteristic | Nephrotoxicity (+) | Nephrotoxicity (−) | P value |
|---|---|---|---|
(n = 41) | (n = 141) | ||
Age (years) | 65.7 ± 9.0 | 65.0 ± 9.6 | 0.69 |
Male sex | 33 (80.5) | 102 (72.3) | 0.12 |
BMI (kg/m2) | 20.4 ± 3.2 | 21.0 ± 3.3 | 0.30 |
Systolic blood pressure (mmHg) | 114.3 ± 15.7 | 119.8 ± 15.4 | 0.0498 |
Diastolic blood pressure (mmHg) | 68.6 ± 9.1 | 71.7 ± 11.4 | 0.08 |
Antihypertensive medication | 14 (34.2) | 37 (26.2) | 0.32 |
 Calcium channel blockers | 9 (22.0) | 26 (18.4) | 0.62 |
 RAS inhibitors | 12 (29.3) | 19 (13.5) | 0.02 |
 Others | 5 (12.2) | 9 (6.4) | 0.22 |
Cardiovascular disease | 1 (2.4) | 9 (6.4) | 0.33 |
Combination of anticancer drugs | 32 (78.1) | 106 (75.2) | 0.71 |
Cisplatin dose (mg/m2) | 73.4 ± 9.6 | 69.8 ± 13.7 | 0.054 |
Amount of hydration (mL/day) | 3,437 ± 319 | 3,345 ± 595 | 0.20 |
Diuretics | 38 (92.7) | 127 (90.1) | 0.61 |
Non-solid food | 21 (51.2) | 50 (35.5) | 0.07 |
Decreased food intake (≤50%) | 9 (22.0) | 18 (12.8) | 0.15 |
Laboratory data | |||
 Creatinine (mg/dL) | 0.69 ± 0.19 | 0.70 ± 0.17 | 0.83 |
 CRP (mg/dL) | 1.01 ± 1.77 | 0.87 ± 1.77 | 0.66 |
 Albumin (g/dL) | 3.80 ± 0.51 | 3.91 ± 0.49 | 0.22 |
 Hemoglobin (g/dL) | 12.7 ± 1.6 | 12.7 ± 1.8 | 0.83 |